PHILADELPHIA, Pa. and OXFORD, UK, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP ), a leader in T-cell therapy to treat cancer, will have updated data from its completed pilot study 1 of NY‑ESO SPEAR T-cell therapy in multiple myeloma patients in the setting of autologous stem cell transplant (ASCT) presented at the annual ASH meeting at the Georgia World Congress Center in Atlanta, Ga.
During an oral presentation, Dr. Edward Stadtmauer, University of Pennsylvania Abramson Cancer Center, will present an update on all twenty-five multiple myeloma patients treated in Adaptimmune’s pilot study in the setting of ASCT. The data cut-off for the abstract was through July 2017, the data cut-off for the oral presentation was August 16, 2017.
Oral Presentation 845: Phase I/IIa Study of Genetically Engineered NY-ESO-1 SPEAR T-Cells Administered Following Autologous Stem Cell Transplant in HLA-a*02+ Patients with Advanced Multiple Myeloma: Long Term Follow‑up (NCT01352286)
Session: 703. Adoptive Immunotherapy: Gene Engineered T cells for Hematologic Malignancies
Time: Monday, December 11, 2017: 5:30 PM (EST)
Location: Bldg. B, Level 2, B206 (Georgia World Congress Center)
Result highlights from the abstract include:
- Overall response rate (ORR) at day 100 was 76% (1 stringent complete response [sCR]; 12 very good partial response [VGPR]; 6 partial response [PR])
- At year 1, 13 patients were progression free (52%) of which 11 were responders (1 sCR; 1 CR; 8 VGPR; 1 PR)
- Three patients remain disease progression-free at 39, 56, and 61 months post T-cell infusion
- Median progression free survival (PFS) was ~13 months (range 3-61 months)
- Eleven of 25 patients (44%) are alive, and median survival was ~35 months (range 6-68 months)
- Autologous GvHD (24%) was reported in 6 patients (3 G3, 3 ≤G2); all resolved with corticosteroids and supportive therapy
- No fatal adverse events have been reported
About Adaptimmune Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Adaptimmune is currently conducting clinical trials with SPEAR T-cells targeting MAGE-A4, -A10, and AFP across several solid tumor indications. GlaxoSmithKline plc (LSE: GSK ) (NYSE: GSK ) exercised its option to exclusively license the right to research, develop, and commercialize Adaptimmune’s NY-ESO SPEAR T-cell therapy program in September 2017. Transition of this program to GSK is ongoing. The Company is located in Philadelphia, USA and Oxfordshire, U.K. For more information, please visit http://www.adaptimmune.com
Forward-Looking Statements This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 2, 2017, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.
Adaptimmune Contacts:
Media Relations: Sébastien Desprez – VP, Communications and Investor Relations T: +44 1235 430 583 M: +44 7718 453 176 Sebastien.Desprez@adaptimmune.com
Investor Relations: Juli P. Miller, Ph.D. – Director, Investor Relations T: +1 215 825 9310 M: +1 215 460 8920 Juli.Miller@adaptimmune.com
________________________
1 This study closed for enrollment in 2015. All NY-ESO studies will ultimately transition to GSK as part of its option exercise over Adaptimmune’s NY‑ESO SPEAR T-cell therapy program that was announced in September 2017.
